Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Large B-Cell, Diffuse 2Fallopian Tube Neoplasms 2Uveal Melanoma 1Thymoma 1Solitary Fibrous Tumor, Pleural 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasms, Unknown Primary 1Neoplasms, Plasma Cell 1Neoplasms 1Mesothelioma, Malignant 1Mediastinal Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Myeloid, Acute 1Glioblastoma 1Eye Neoplasms 1Congenital Abnormalities 1Carcinoma, Ovarian Epithelial 1Carcinoma, Neuroendocrine 1Burkitt Lymphoma 1Brenner Tumor 1Bone Marrow Neoplasms 1

Interventions

Cyclophosphamide 109Rituximab 62Etoposide 56Methotrexate 53Cytarabine 53Peripheral Blood Stem Cell Transplantation 47Vincristine 46Filgrastim 43fludarabine phosphate 41Radiotherapy 37Doxorubicin 36Mycophenolic Acid 35Tacrolimus 33Busulfan 33Whole-Body Irradiation 32Prednisone 31Methylprednisolone 27Dexamethasone 27Antilymphocyte Serum 27Cyclosporine 26Melphalan 24merphos 21blinatumomab 21Leucovorin 21Granulocyte Colony-Stimulating Factor 16Carmustine 15Calcium Dobesilate 15fludarabine 14Mercaptopurine 14Ifosfamide 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Burkitt Lymphoma × belinostat × Clear all
NCT00303953 2014-05-12

PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
22 enrolled 8 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡